| FRI, JUL 17, 2020 | | | Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.
The U.S. coronavirus outbreak continues to worsen and people who are asymptomatic may be playing a large role in transmission, according to a top HHS official. Adm. Brett Giroir, the assistant secretary for HHS, told CNBC on Friday that most transmission of the virus is coming from people who never develop symptoms. The statement came as state health officials warn more young people, who may otherwise appear healthy, are getting infected with the virus at a higher rate. We have more on the outbreak below.
| 'Critical' data gone after Trump administration shifted control from CDC | The Trump administration quietly directed states starting Wednesday to stop sending hospital data to the CDC and reroute it directly to the HHS instead. The sudden change, coupled with the disappearance of the data from the CDC's website Tuesday spurred outcry from researchers, state governors and lawmakers on Capitol Hill. An HHS official told me the current data will be back "in a few days" and CDC reposted all of its old data on Thursday. Ryan Panchadsaram, who helps run a data-tracking site called Covid Exit Strategy, said it's a major loss for his site, which grades each state's response to the pandemic. -Will Feuer | | Long-awaited Moderna vaccine data arrives, and a look at execs' stock sales | We got an initial peek at Moderna's phase 1 clinical trial results for its Covid-19 vaccine in May, but this week the New England Journal of Medicine, at long last, published the whole study. The results, while early, were promising to Wall Street, and Moderna's chief medical officer, Dr. Tal Zaks, told us on "Squawk Box" he expects the vaccine should be protective against infection. The key question is: how protective, and for how long? That's what the 30,000-participant phase 3 trial, set to start July 27, should tell us – along with important answers about the vaccine's safety and tolerability. Meanwhile, another story's been swirling around Moderna: stock sales from its executive team amounting to $171 million year-to-date. Moderna notes they're all under pre-programmed plans known as 10b5-1's. Here's a breakdown of the sales. -Meg Tirrell | | Covid is upending the outlook for health insurance | One New England insurer tells me it's near impossible to know how much patients will continue to postpone care or how to properly price insurance policies next year, amid the resurgence of the virus. UnitedHealth Group echoed this insight on its earnings call, saying commercial renewals are running two months behind normal. But the clock is ticking -- 2021 open enrollment season is just over three months away. -Bertha Coombs | | WHO officials say coronavirus antibodies may wane after several months | World Health Organization officials said Monday that patients who recover from the coronavirus may be able to get the virus again, adding that studies suggest their immunity may wane after a few months. Dr. Maria Van Kerkhove, head of the WHO's emerging diseases and zoonosis unit, said while patients "do mount some level of an immune response," more research is needed for scientists to fully understand the virus. In the case of Covid-19, health officials have said there is insufficient data to indicate that antibodies ensure immunity against the virus. -Jasmine Kim | | CNBC kicked off a new series this week looking at international responses to Covid-19 | It's been several months since the WHO declared Covid-19 to be a pandemic. Countries around the world responded very differently as they looked for ways to balance keeping people safe while avoiding widespread unemployment. One of the best examples so far comes from Taiwan, which has a population of more than 23 million people but reported just 451 Covid-19 cases and 7 deaths. What went right? Well, according to more than half-a-dozen experts, it's all about leadership. Taiwan has had a plan in place since the SARS epidemic of 2003, and stuck to it – with no exceptions. It closed its borders early – back in late January – and required a two-week quarantine for any returning citizens. Masks were doled out carefully to ensure there were enough for everyone, and public health officials provided clear rules via regular briefings. -Chrissy Farr | | WHO warns against using schools as a 'political football' | WHO officials warned global leaders Monday against turning the decision to reopen schools "into yet another political football in this game," adding that children will be exposed to the virus and some will be infected and spread it to others. "My fear in this is that we create these political footballs that get kicked around the place," Dr. Mike Ryan, executive director of the WHO's health emergencies program, said at a news conference. Some of the largest school districts in the U.S. have already announced they'll begin the school year this fall strictly online even as the Trump administration ramps up its effort to return students to campus. -Noah Higgins-Dunn | | Warren and Sanders slam Trump for giving Gilead 'windfall' drug deal | In a new letter addressed to HHS Secretary Alex Azar that was obtained by CNBC, Sens. Elizabeth Warren and Bernie Sanders slammed the Trump administration for giving Gilead Sciences a "windfall" deal to secure most of the pharmaceutical company's supply of its coronavirus-fighting drug remdesivir to the United States. The deal gives the U.S. more than 500,000 treatment courses of the antiviral drug for U.S. hospitals through September. Gilead said it would sell remdesivir for $520 per vial in the U.S. to patients with private insurance and $390 per vial to federal insurance programs like Medicare, as well as foreign countries. The senators said the deal will give Gilead hundreds of millions in revenue, borne almost entirely by American taxpayers. -Berkeley Lovelace Jr. | Small Business Playbook | August 12, 2020
Small businesses power the U.S. economy, but today are facing unprecedented challenges. The CNBC Small Business Playbook virtual summit will help business owners overcome these challenges with actionable advice and best practices. Informed by proprietary data and using the power of the world's leading business network, we'll gather the most trusted and inspirational voices in business, along with small business subject-area experts, to provide small business owners the resources to survive today's crisis and provide a path forward for the future.
Who should join: This program is geared toward small business owners and leaders. | |
Post a Comment